4ET 2124
Alternative Names: 4ET-2124Latest Information Update: 03 Oct 2023
At a glance
- Originator 4E Therapeutics
- Class Analgesics; Small molecules
- Mechanism of Action MKNK1 protein inhibitors; MKNK2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Migraine
Most Recent Events
- 03 Oct 2023 Pharmacodynamics data from a preclinical studies released by 4E Therapeutics, prior to September 2023 (4E Therapeutics pipeline, September 2023)
- 20 Sep 2023 4E Therapeutics has patents pending for MNK inhibitors Worldwide
- 18 Sep 2023 Preclinical trials in Migraine in USA (unspecified route), prior to September 2023 (4E Therapeutics pipeline, September 2023)